Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interdisciplinary therapy of Ewing sarcoma]

H Jürgens1

  • 1Abteilung Pädiatrische Hämatologie/Onkologie, Westfälische Wilhelms-Universität, Münster.

Praxis
|September 12, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

[Adherence to Long-term Follow-up in Paediatric Oncology--Results of a Monocentric Analysis].

Klinische Padiatrie·2015
Same author

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

[The randomisation issue - autonomy vs. heteronomy].

Klinische Padiatrie·2014
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Ewing's sarcoma, a rare childhood bone cancer, is treatable with combined therapies. Early diagnosis and integrated treatment improve survival rates for localized disease.

Area of Science:

  • Pediatric Oncology
  • Skeletal Malignancies
  • Cancer Biology

Context:

  • Ewing's sarcoma is a prevalent bone tumor in young children.
  • It is a highly malignant neoplasm originating in bone or soft tissues.
  • Localized disease often presents with micrometastases, necessitating multimodal treatment.

Purpose:

  • To outline the current understanding and treatment strategies for Ewing's sarcoma.
  • To emphasize the importance of integrating surgery, radiotherapy, and chemotherapy.
  • To highlight diagnostic advancements and their impact on patient outcomes.

Summary:

  • Multimodal therapy, including chemotherapy, surgery, and radiotherapy, is crucial for eradicating Ewing's sarcoma and its micrometastases.
  • Treatment aggressiveness is tailored to the extent of the disease.

Related Experiment Videos

  • Advanced diagnostic tools like imaging, immunohistochemistry, and cytogenetics aid in evaluation.

    • Impact:

    • Optimal integration of therapies aims to maximize tumor eradication while preserving patient function.
    • Significant improvements in prognosis are observed for non-metastatic Ewing's sarcoma.
    • Achieving 80% local control and a two-thirds 5-year disease-free survival rate for non-metastatic cases.